The therapeutic effect of decavatinib on psoriasis and patient feedback

Deucravacitinib is an oral selective Tyk2 inhibitor, a new generation of small molecule targeted drugs, mainly used to treat patients with moderate to severe plaque psoriasis. Tyk2 is a member of the Janus kinase family. It participates in the regulation of inflammatory signaling pathways such as IL-12 and IL-23 and plays a central role in the pathogenesis of psoriasis. By selectively inhibiting Tyk2, deuterated colexitinib can reduce the release of inflammatory mediators, thereby alleviating the symptoms of skin erythema, scale and plaque thickening, and providing patients with a new oral treatment option of non-biological agents.

In clinical trials, deuterated colexitinib has shown significant therapeutic effects. POETYK The results of two key Phase 3 studies of PSO-1 and PSO-2 showed that approximately 58%-59% of patients with moderate to severe plaque psoriasis who received 12 weeks of treatment had a 58%-59% of patients achieved PASI75 (that is, the psoriasis area and severity index improved by 75%), while the PASI75 compliance rate in the biological agent or traditional systemic treatment group is usually around 30%-40%. In addition, some patients still maintained efficacy during long-term follow-up at 24 weeks and 52 weeks, indicating that the drug has a sustainable control effect.

Actual feedback from patients shows that deuterated colexitinib has obvious advantages in terms of convenience of use and improvement in quality of life. As an oral drug, it does not require injections or complicated preparations, and the use experience is relatively friendly; patients generally experience improvement in skin symptoms after several weeks of treatment, such as reduced erythema, reduced scales, and relief of itching. At the same time, psychological stress and social barriers are also relieved to a certain extent. Patients also report that oral medications are easier to take regularly and schedule in daily life than injectable biologics, thereby improving long-term compliance.

In terms of safety, deuterated colexitinib was generally well tolerated. Common adverse reactions include upper respiratory tract infection, headache, fatigue, diarrhea, etc. Most of them are mild to moderate and can be self-limited or relieved through symptomatic treatment. Compared with traditional JAK inhibitors, Tyk2 is highly selective and reduces the risk ofJAK1/2/3 inhibition, so the risk of cardiovascular, blood lipid and thrombotic events is low, but hematological indicators and liver and kidney function still need to be monitored regularly. Patient feedback shows that most adverse reactions are mild and acceptable, and only a few patients need to adjust the dose or suspend medication due to skin rash or gastrointestinal discomfort.

Overall, deuterated colexitinib showed significant efficacy and good tolerability in patients with moderate to severe plaque psoriasis. Clinical trials and real-world use feedback have shown that the drug can quickly reduce skin symptoms and improve quality of life, while maintaining the convenience of oral treatment. Deuterated colexitinib provides a safe, effective, and convenient treatment option for patients who have difficulty tolerating injectable biologics or respond poorly to traditional systemic treatments. In the future, as more long-term data and real-world studies accumulate, the drug's status in psoriasis treatment strategies is expected to be further enhanced, providing patients with a sustainable and controllable management solution.

Reference materials:https://www.drugs.com/